Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.

Poggesi I, Li LY, Jiao J, Hellemans P, Rasschaert F, de Zwart L, Snoeys J, De Meulder M, Mamidi RNVS, Ouellet D.

Eur J Drug Metab Pharmacokinet. 2019 Oct 31. doi: 10.1007/s13318-019-00581-9. [Epub ahead of print]

PMID:
31673875
2.

Population pharmacokinetics of trabectedin in adolescent patients with cancer.

Poggesi I, Valenzuela B, Ouellet D, Gonzalez M, Hillewaert V, Baruchel S, Fox E, Perez-Ruixo JJ.

Cancer Chemother Pharmacol. 2019 Oct;84(4):707-717. doi: 10.1007/s00280-019-03899-y. Epub 2019 Jul 8.

PMID:
31286189
3.

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.

Bahleda R, Italiano A, Hierro C, Mita A, Cervantes A, Chan N, Awad M, Calvo E, Moreno V, Govindan R, Spira A, Gonzalez M, Zhong B, Santiago-Walker A, Poggesi I, Parekh T, Xie H, Infante J, Tabernero J.

Clin Cancer Res. 2019 Aug 15;25(16):4888-4897. doi: 10.1158/1078-0432.CCR-18-3334. Epub 2019 May 14.

PMID:
31088831
4.

Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.

Lavezzi SM, de Jong J, Neyens M, Cramer P, Demirkan F, Fraser G, Bartlett N, Dilhuydy MS, Loscertales J, Avigdor A, Rule S, Samoilova O, Goy A, Ganguly S, Salman M, Howes A, Mahler M, De Nicolao G, Poggesi I.

Pharm Res. 2019 May 1;36(7):93. doi: 10.1007/s11095-019-2605-8.

PMID:
31044267
5.

Population Pharmacokinetic Analysis of Decitabine in Pediatric Patients With Acute Myeloid Leukemia.

Zhou W, Parasrampuria DA, Nemat S, Nakahara S, Poggesi I, Massarella J, Zhang L, Appiani C.

J Clin Pharmacol. 2019 May;59(5):668-676. doi: 10.1002/jcph.1357. Epub 2018 Dec 11.

PMID:
30536675
6.

Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.

Calvo E, Azaro A, Rodon J, Dirix L, Huizing M, Senecal FM, LoRusso P, Yee L, Poggesi I, de Jong J, Triantos S, Park YC, Knoblauch RE, Parekh TV, Demetri GD, von Mehren M.

Invest New Drugs. 2018 Jun;36(3):476-486. doi: 10.1007/s10637-017-0546-9. Epub 2017 Nov 27.

PMID:
29177975
7.

Mathematical modeling of efficacy and safety for anticancer drugs clinical development.

Lavezzi SM, Borella E, Carrara L, De Nicolao G, Magni P, Poggesi I.

Expert Opin Drug Discov. 2018 Jan;13(1):5-21. doi: 10.1080/17460441.2018.1388369. Epub 2017 Oct 12. Review.

PMID:
28972401
8.

Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs.

Borella E, Poggesi I, Magni P.

Clin Pharmacokinet. 2018 Apr;57(4):505-514. doi: 10.1007/s40262-017-0574-9.

PMID:
28667460
9.

Current mathematical models for cancer drug discovery.

Carrara L, Lavezzi SM, Borella E, De Nicolao G, Magni P, Poggesi I.

Expert Opin Drug Discov. 2017 Aug;12(8):785-799. doi: 10.1080/17460441.2017.1340271. Epub 2017 Jun 22. Review.

PMID:
28595492
10.

Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer.

Xu XS, Ryan CJ, Stuyckens K, Smith MR, Saad F, Griffin TW, Park YC, Yu MK, De Porre P, Vermeulen A, Poggesi I, Nandy P.

Clin Pharmacokinet. 2017 Jan;56(1):55-63. doi: 10.1007/s40262-016-0425-0.

PMID:
27324190
11.

Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis.

Sardu ML, Poggesi I, De Nicolao G.

J Pharmacokinet Pharmacodyn. 2015 Dec;42(6):611-26. doi: 10.1007/s10928-015-9427-z. Epub 2015 Jul 26.

PMID:
26209955
12.

Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients.

Xu XS, Ryan CJ, Stuyckens K, Smith MR, Saad F, Griffin TW, Park YC, Yu MK, Vermeulen A, Poggesi I, Nandy P.

Clin Cancer Res. 2015 Jul 15;21(14):3170-7. doi: 10.1158/1078-0432.CCR-14-1549. Epub 2015 Mar 31.

13.

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.

Marostica E, Sukbuntherng J, Loury D, de Jong J, de Trixhe XW, Vermeulen A, De Nicolao G, O'Brien S, Byrd JC, Advani R, McGreivy J, Poggesi I.

Cancer Chemother Pharmacol. 2015 Jan;75(1):111-21. doi: 10.1007/s00280-014-2617-3. Epub 2014 Nov 8.

PMID:
25381051
14.

Some considerations on the predictions of pharmacokinetic alterations in subjects with liver disease.

Gonzalez M, Goracci L, Cruciani G, Poggesi I.

Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1397-408. doi: 10.1517/17425255.2014.952628. Review.

PMID:
25219632
15.

Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer.

Stuyckens K, Saad F, Xu XS, Ryan CJ, Smith MR, Griffin TW, Yu MK, Vermeulen A, Nandy P, Poggesi I.

Clin Pharmacokinet. 2014 Dec;53(12):1149-60. doi: 10.1007/s40262-014-0178-6.

PMID:
25204404
16.

The successes and failures of physiologically based pharmacokinetic modeling: there is room for improvement.

Poggesi I, Snoeys J, Van Peer A.

Expert Opin Drug Metab Toxicol. 2014 May;10(5):631-5. doi: 10.1517/17425255.2014.888058. Epub 2014 Feb 11.

PMID:
24517185
17.

Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET.

Ridler K, Gunn RN, Searle GE, Barletta J, Passchier J, Dixson L, Hallett WA, Ashworth S, Gray FA, Burgess C, Poggesi I, Bullman JN, Ratti E, Laruelle MA, Rabiner EA.

J Psychopharmacol. 2014 Mar;28(3):244-53. doi: 10.1177/0269881113517953. Epub 2014 Jan 15.

PMID:
24429221
18.

Modeling of human tumor xenografts and dose rationale in oncology.

Simeoni M, De Nicolao G, Magni P, Rocchetti M, Poggesi I.

Drug Discov Today Technol. 2013 Sep;10(3):e365-72. doi: 10.1016/j.ddtec.2012.07.004. Review.

PMID:
24050133
19.

Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.

Rocchetti M, Germani M, Del Bene F, Poggesi I, Magni P, Pesenti E, De Nicolao G.

Cancer Chemother Pharmacol. 2013 May;71(5):1147-57. doi: 10.1007/s00280-013-2107-z. Epub 2013 Feb 21.

PMID:
23430120
20.

Combined NK₁ antagonism and serotonin reuptake inhibition: effects on emotional processing in humans.

Harmer CJ, Dawson GR, Dourish CT, Favaron E, Parsons E, Fiore M, Zucchetto M, Bifone A, Poggesi I, Fernandes S, Alexander RC, Goodwin GM.

J Psychopharmacol. 2013 May;27(5):435-43. doi: 10.1177/0269881112472558. Epub 2013 Feb 12.

PMID:
23407644
21.

Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development.

Bernard A, Kimko H, Mital D, Poggesi I.

Expert Opin Drug Metab Toxicol. 2012 Sep;8(9):1057-69. doi: 10.1517/17425255.2012.693480. Epub 2012 May 26. Review.

PMID:
22632710
22.

Joint modeling of efficacy, dropout, and tolerability in flexible-dose trials: a case study in depression.

Russu A, Marostica E, De Nicolao G, Hooker AC, Poggesi I, Gomeni R, Zamuner S.

Clin Pharmacol Ther. 2012 May;91(5):863-71. doi: 10.1038/clpt.2011.322.

PMID:
22472989
23.

Bayesian population modeling of phase I dose escalation studies: Gaussian process versus parametric approaches.

Russu A, Poggesi I, Gomeni R, De Nicolao G.

IEEE Trans Biomed Eng. 2011 Nov;58(11):3156-64. doi: 10.1109/TBME.2011.2164614. Epub 2011 Aug 15.

PMID:
21846598
24.

Bayesian population approaches to the analysis of dose escalation studies.

Russu A, De Nicolao G, Poggesi I, Neve M, Gomeni R.

Comput Methods Programs Biomed. 2012 Aug;107(2):189-201. doi: 10.1016/j.cmpb.2011.05.010. Epub 2011 Jul 20.

PMID:
21764475
25.

Current and future directions of pharmacokinetic and pharmacokinetic-pharmacodynamic modelling and simulation: population approach group in Europe 19th annual meeting.

Kloft C, Poggesi I.

Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1599-604. doi: 10.1517/17425255.2010.529899. Epub 2010 Oct 24.

PMID:
20969486
26.

Re: Antitumor efficacy testing in rodents.

Poggesi I, de Nicolao G, Germani M, Rocchetti M.

J Natl Cancer Inst. 2009 Nov 18;101(22):1592-3; author reply 1593-4. doi: 10.1093/jnci/djp356. Epub 2009 Oct 28. No abstract available.

PMID:
19864637
27.

Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach.

Rocchetti M, Del Bene F, Germani M, Fiorentini F, Poggesi I, Pesenti E, Magni P, De Nicolao G.

Eur J Cancer. 2009 Dec;45(18):3336-46. doi: 10.1016/j.ejca.2009.09.025. Epub 2009 Oct 23.

PMID:
19854637
28.

Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity.

Nucci G, Gomeni R, Poggesi I.

Expert Opin Drug Discov. 2009 Aug;4(8):837-56. doi: 10.1517/17460440903036073. Epub 2009 Jun 24.

PMID:
23496270
29.

From pharmacokinetics to therapeutics.

Church MK, Gillard M, Sargentini-Maier ML, Poggesi I, Campbell A, Benedetti MS.

Drug Metab Rev. 2009;41(3):455-74. doi: 10.1080/10837450902891535. Review.

PMID:
19601722
30.

Pharmacokinetics in special populations.

Poggesi I, Benedetti MS, Whomsley R, Le Lamer S, Molimard M, Watelet JB.

Drug Metab Rev. 2009;41(3):422-54. doi: 10.1080/10837450902891527. Review.

PMID:
19601721
31.

Physiologically based pharmacokinetics (PBPK).

Espié P, Tytgat D, Sargentini-Maier ML, Poggesi I, Watelet JB.

Drug Metab Rev. 2009;41(3):391-407. doi: 10.1080/10837450902891360. Review.

PMID:
19601719
32.

Drug metabolism and pharmacokinetics.

Benedetti MS, Whomsley R, Poggesi I, Cawello W, Mathy FX, Delporte ML, Papeleu P, Watelet JB.

Drug Metab Rev. 2009;41(3):344-90. doi: 10.1080/10837450902891295. Review.

PMID:
19601718
33.

A minimal model of tumor growth inhibition.

Magni P, Germani M, De Nicolao G, Bianchini G, Simeoni M, Poggesi I, Rocchetti M.

IEEE Trans Biomed Eng. 2008 Dec;55(12):2683-90. doi: 10.1109/TBME.2008.913420.

PMID:
19126447
34.

First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.

Menichincheri M, Bargiotti A, Berthelsen J, Bertrand JA, Bossi R, Ciavolella A, Cirla A, Cristiani C, Croci V, D'Alessio R, Fasolini M, Fiorentini F, Forte B, Isacchi A, Martina K, Molinari A, Montagnoli A, Orsini P, Orzi F, Pesenti E, Pezzetta D, Pillan A, Poggesi I, Roletto F, Scolaro A, Tatò M, Tibolla M, Valsasina B, Varasi M, Volpi D, Santocanale C, Vanotti E.

J Med Chem. 2009 Jan 22;52(2):293-307. doi: 10.1021/jm800977q. Erratum in: J Med Chem. 2009 Feb 26;52(4):1230.

PMID:
19115845
35.

Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.

Traina TA, Poggesi I, Robson M, Asnis A, Duncan BA, Heerdt A, Dang C, Lake D, Moasser M, Panageas K, Borgen P, Norton L, Hudis C, Dickler MN.

Breast Cancer Res Treat. 2008 Sep;111(2):377-88. Epub 2007 Oct 20.

PMID:
17952589
36.

Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems.

Crivori P, Morelli A, Pezzetta D, Rocchetti M, Poggesi I.

Eur J Pharm Sci. 2007 Nov;32(3):169-81. Epub 2007 Aug 21.

PMID:
17714921
37.

Predicting the active doses in humans from animal studies: a novel approach in oncology.

Rocchetti M, Simeoni M, Pesenti E, De Nicolao G, Poggesi I.

Eur J Cancer. 2007 Aug;43(12):1862-8. Epub 2007 Jul 2.

PMID:
17604156
38.

Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study.

Germani M, Crivori P, Rocchetti M, Burton PS, Wilson AG, Smith ME, Poggesi I.

Eur J Pharm Sci. 2007 Jul;31(3-4):190-201. Epub 2007 Mar 24.

PMID:
17481865
39.

Computational models for identifying potential P-glycoprotein substrates and inhibitors.

Crivori P, Reinach B, Pezzetta D, Poggesi I.

Mol Pharm. 2006 Jan-Feb;3(1):33-44.

PMID:
16686367
40.

Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs.

Crivori P, Poggesi I.

Eur J Med Chem. 2006 Jul;41(7):795-808. Epub 2006 Apr 27. Review.

PMID:
16644065
41.

A mathematical model to study the effects of drugs administration on tumor growth dynamics.

Magni P, Simeoni M, Poggesi I, Rocchetti M, De Nicolao G.

Math Biosci. 2006 Apr;200(2):127-51. Epub 2006 Mar 3.

PMID:
16516246
42.

A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation.

Valle M, Di Salle E, Jannuzzo MG, Poggesi I, Rocchetti M, Spinelli R, Verotta D.

Br J Clin Pharmacol. 2005 Mar;59(3):355-64.

43.

A pharmacokinetic-pharmacodynamic model for predicting tumour growth inhibition in mice: a useful tool in oncology drug development.

Rocchetti M, Poggesi I, Germani M, Fiorentini F, Pellizzoni C, Zugnoni P, Pesenti E, Simeoni M, De Nicolao G.

Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):265-8. No abstract available.

44.

Evaluation of a physiologically-based pharmacokinetic approach for simulating the first-time-in-animal study.

Germani M, Crivori P, Rocchetti M, Burton PS, Wilson AG, Smith ME, Poggesi I.

Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):254-6. No abstract available.

45.

Predictive model for identifying potential CYP2D6 inhibitors.

Crivori P, Poggesi I.

Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):251-3. No abstract available.

46.

Model based on GRID-derived descriptors for estimating CYP3A4 enzyme stability of potential drug candidates.

Crivori P, Zamora I, Speed B, Orrenius C, Poggesi I.

J Comput Aided Mol Des. 2004 Mar;18(3):155-66.

PMID:
15368916
47.

The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.

Jannuzzo MG, Poggesi I, Spinelli R, Rocchetti M, Cicioni P, Buchan P.

Cancer Chemother Pharmacol. 2004 Jun;53(6):475-81. Epub 2004 Mar 11.

PMID:
15014897
48.

Predicting human pharmacokinetics from preclinical data.

Poggesi I.

Curr Opin Drug Discov Devel. 2004 Jan;7(1):100-11. Review.

PMID:
14982153
49.

Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.

Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M.

Cancer Res. 2004 Feb 1;64(3):1094-101.

50.

In vitro cell growth pharmacodynamic studies: a new nonparametric approach to determining the relative importance of drug concentration and treatment time.

Germani M, Magni P, De Nicolao G, Poggesi I, Marsiglio A, Ballinari D, Rocchetti M.

Cancer Chemother Pharmacol. 2003 Dec;52(6):507-13. Epub 2003 Aug 16.

PMID:
12923660

Supplemental Content

Loading ...
Support Center